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Abstract 
Purpose: To investigate the effect of β3-adrenoceptors (β3-AR) up-regulation on fibrosis in cardiac 
fibroblast cells in rats and its potential mechanism.  
Methods: Cardiac fibroblast cells (CFB) were isolated and identified from rats’ hearts. The β3-ARup-
regulated cardiac fibroblast cells were constructed by lentiviral transfection technology. Thereafter, Ang 
II was used to induce fibrosis in cardiac fibroblast cells, and subsequently, Western blot assay was 
performed to investigate fibrosis related marker proteins (TGF-β, Smad-2, p-Smad-2, Col-I and Col-III) 
in cardiac fibroblast cells. 
Results: β3-AR up-regulated cardiac fibroblast cells were successfully constructed. Furthermore, the 
results show that up-regulation of β3-AR increased the expressions of TGF-β, p-Smad-2, Col-I and Col-
III proteins in Ang II treated cardiac fibroblast cells.  
Conclusion: The results suggest that up-regulation of β3-AR aggravates fibrosis of cardiac fibroblast 
cells. In other words, inhibition of β3-AR expressions in cardiac tissues would be beneficial for treating 
cardiac fibrosis and its related cardiac diseases. 
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Cardiovascular disease is one of the leading 
causes of death all over the world [1]. Cardiac 
fibrosis is characterized by excessive deposition 
of collagenous fiber in the extracellular matrix 
(ECM) and disproportionate increase and 
disordered arrangement of myocardial collagen 
[2-4]. Increasing evidence demonstrated that 
cardiac fibrosis (CF) is a central factor for the 
development of several serious cardiovascular 
diseases, including cardiac failure, myocardial 
infarction and cardiac hypertrophy, etc [2,4-6]. 
Therefore, discovering more novel reliable 
cardiac fibrosis interventions might be a feasible 
approach to cure various serious heart diseases. 
 
Previous investigations revealed that β3-
Adrenoceptors (β3-AR) is lowly expressed in 
normal human and animal ventricle myocardium, 
and the activation of β3-AR could affect 
myocardial contraction and plays an important 
role in the pathogenesis of cardiac dysfunction 
[7-9]. However, so far, there is no reported work 
regarding the effects of β3-AR on cardiac 
fibrosis, thus our present study is designed to 
investigate the potential of β3-AR on fibrosis in 
cardiac fibroblast cell and its potential 
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mechanism. In our present work, β3-AR over-
regulated cardiac fibroblast cells were 
constructed by lentiviral transfection. Then, Ang 
II was used to induce fibrosis in the cardiac 
fibroblast cell, and subsequently western blot 
assay was performed to investigate the fibrosis 







SD sucking rats (1 - 3 days), purchased from the 
experimental animal center of the first affiliated 
hospital of Xinjiang Medical University (Urumqi, 
China), were used in the present investigation. 
The protocol for the use of animals was 
according to the guidelines of animal 
experiments from the ethical committee for 
animal research of the First Affiliated Hospital of 
the Medical College, Shihezi University (ethical 
approval o.: S2013-04-02). 
 
Reagents and chemicals 
 
The resulting recombinant lenti viruses 
(Objective gene sequence number: 
NM_013108.2) were purchased from Cyagen 
Biosciences Inc., (Guangzhou, China). DMEM 
medium and fetal bovine serum (FBS) were 
purchased from Gibco Co. (Shanghai, China); 
β3-ARprimary antibody was purchased from 
Santcruz Co. (Japan), TGF-β and Collagen-III 
(Col-III) primary antibodies were purchased from 
Protein tech Co. (USA), Smad-2/3, Phospho-
Smad-2,vimentin, horseradish- peroxidase-
conjugated secondary antibodies and GAPDH 
primary antibodies were purchased from Cell 
Signaling Co. (USA), Col-III primary antibody 
was purchased from Abcam (UK); BCA protein 
assay kit was purchased from Beyotime 
(Jiangsu, China). All other regents and chemical 
used in our present study were analytical grade.  
 
Primary culture of rat ventricular cardiac 
fibroblasts 
 
Rat cardiac fibroblasts were isolated and cultured 
according to previously described method [4]. 
Briefly, hearts of the rats were removed and 
chopped into 1 mm3 pieces, then digested in 0.1 
% type II collagenase and 0.25 % trypsin. 
Subsequently, the cell suspension was 
centrifuged to collect the cell pellet, then the cell 
pellet was re-suspended with DMEM containing 
10 % FBS. After 1 h incubation in culture flask, 
the attached cells were further cultured at 37 °C 
in a humidified and 5 % CO2 atmosphere. The 
isolated cardiac fibroblasts were identified by 
using the immunofluorescence assay with 
vimentin protein, and our results showed that the 
vimentin protein positive cells accounted for 
more than 95 % (Figure 1). The second to fourth 





Figure 1: Identification of the isolated cardiac fibroblasts using immunofluorescence assay. Cells were stained 
with DAPI and anti-vimentin antibody, and the blue fluorescence represented the nucleus and green fluorescence 
represented the vimentin proteins 
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Preparation of β3-AR up-regulated cardiac 
fibroblast cells 
 
The β3-AR gene siRNA vector recombinant 
plasmid was constructed using RNA interference 
technique. Then the resulting recombinant 
lentiviruses were used to infect cardiac fibroblast 
cells to up-regulate the β3-AR. The expression of 
β3-AR in normal cardiac fibroblast cells (N-CFC), 
cardiac fibroblasts cells with β3-AR up-regulation 
(CFC-β3-AR), and cardiac fibroblast cells treated 
with control vector (EC) were detected using 
western blotting and fluorescence microscope 
observation. In addition, flow cytometry assay 
was performed to determine the transfection rate. 
 
Western blot  
 
After lentiviral transfection, the cardiac fibroblast 
cells were induced to fibrosis by treating with Ang 
II (10-6M) for 24 h [4,10]. Then, the cardiac 
fibroblast cells were cultured for extraction of 
total proteins. Subsequently, the protein 
concentration was determined using the BCA 
Protein Assay kit. Then equal amounts of 
proteins (35 μg) were separated by SDS/PAGE, 
blotted on PVDF membrane and probed with 
various primary antibodies (including β3-AR, 
TGF-β, Smad-2, Col-I and Col-III), followed by 
incubation with the secondary antibodies and 
chemiluminescence detection. To normalize for 
protein loading, antibodies directed against 




Data are expressed as mean ± SD of three 
independent experiments. Statistical analysis 
was carried out using SPSS 15.0 software 
package and one way analysis of variance 
(ANOVA) with Dunnett’s test to compare the 
means between two groups with a significance 
level of p < 0.05. 
RESULTS 
 
Expression of β3-AR in cardiac fibroblast 
cells after transfection 
 
As can be seen from our results of fluorescence 
microscope assay which is shown in Figure 2A, 
after transfection, the β3-AR proteins were 
significantly up-regulated in the cardiac fibroblast 
cells, compared with both the N-CFC and EC 
groups, and the results of the flow cytometry 
assay showed that the transfection rate was 
nearly 70 %. Furthermore, the western blot 
results also indicated that β3-AR proteins 
expressions increased after transfection (Figure 
3). These results suggest that the cardiac 
fibroblast cells with β3-AR up-regulation were 
constructed successfully. 
 
Effect of β3-AR up-regulation  
 
After being induced by Ang II for 24 h, TGF-β, 
Smad-2, Col-I and Col-III expressions in cardiac 
fibroblast cells were determined by western 
blotting assay. As can be seen from Figure 4, our 
results showed that no change was observed for 
Smad-2 expressions among all the test groups. 
However, it is interesting that TGF-βand p-Smad-
2 were significantly up-regulated in β3-AR up-
regulated cardiac fibroblast cells, compared with 
the N-CFC, AgII-EC and Ag II-CFC. Furthermore, 
the collagen types I and III proteins (Col-I and III) 
were also determined in our present study, and 
our results revealed that both Col-I and Col-III 
were up-regulated in cardiac fibroblast cells by 
up regulation of the β3-AR (Figure 5). These 
results indicate that up-regulation of β3-AR could 






Figure 2: Results of the transfection. A. Results of the fluorescence microscope assay, a-c represent the normal 
cardiac fibroblast cells, cardiac fibroblast cells with β3-AR up-regulation, and cardiac fibroblast cells treated with 
control vector, respectively. B. Results of the flow cytometry assay 
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Figure 3: Expression ofβ3-AR in cardiac fibroblast cells after transfection. Protein expressions of β3-AR were 
determined by western blotting. N-CFC means the normal cardiac fibroblast cells CFC-β3-AR means withβ3-AR 
up-regulation, and EC means cardiac fibroblast cells treated with control vector 
 
 
Figure 4: Results of expression of TGF-β/Smad-2. Protein expressions were determined by western blotting. N-
CFC means the normal cardiac fibroblast cells (CFC), AgII-CFC-β3-AR means CFC-β3-ARtreated by AngII, and 
AgII-EC means EC treated by AngII 
 
 
Figure 5: Results of expression of Col-I/Col-III. Protein expressions were determined by western blotting. N-CFC 
means the normal cardiac fibroblast cells (CFC), AgII-CFC-β3-AR means CFC-β3-ARtreated by AngII, and AgII-




Tissue fibrosis can result in certain serious 
diseases for which effective therapy is lacking 
[11]. For the heart, cardiac fibrosis damages 
cardiac contraction and causes cardiac 
dysfunction [2]. Therefore, inhibition of cardiac 
fibrosis would be beneficial for improving some 
serious cardiac diseases. To the best of our 
knowledge, the present work is the first reported 
study on the effect of β3-AR on the development 
of cardiac fibrosis, which has significant 
reference value for the future treatment of 
cardiac diseases in the clinic. 
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β3-AR is commonly expressed at low levels in 
cardiac tissues, and previous research revealed 
that β3-AR would be up-regulated in patients 
with dilated cardiomyopathy [8]. Therefore, we 
guessed that β3-AR might play an important role 
in the pathogenesis of cardiac fibrosis. In our 
study, the lentivirus transfection technology was 
used to construct the β3-AR over-expressed 
cardiac fibroblast cells. Previous reports have 
demonstrated that Ang II is a well-established 
factor related to many cardiac diseases and 
could induce the development of cardiac fibrosis 
[12,13]. Thus, Ang II induced cardiac fibrosis 
strategy is a commonly used experimental model 
both in vivo and in vitro [4,14,15]. In our present 
study, the fibrotic cardiac fibroblasts cells were 
induced successfully with Ang II. TGF-β/Smads 
is a well-known pathway involved in multi-organ 
tissue fibrosis via inducing endothelial-
mesenchymal transition (EndMT) and vascular 
remodeling, etc. [16,17]. TGF-β acts by 
activating Smads signaling pathway via 
phosphorylating the Smad-2/3 proteins. The p-
Smads subsequently translocates from the 
cytoplasm into the nucleus to regulate other 
transcription factors [18,19]. Therefore, the 
expressions of TGF-β/Smads could reflect the 
extent of cardiac fibrosis. Furthermore, collagen 
is the most abundant protein in animal tissues 
and also the major component in the interstitial 
extracellular matrix. Previous researches have 
revealed that Col-I and Col-III would be over-
expressed in patients with cardiac fibrosis, and 
Col-I/III could be considered as the biomarkers of 
cardiac fibrosis [20,21]. In our present 
investigation, up-regulation of β3-AR increased 
the expressions of Col- I and Col- III. Both our 
results mentioned above suggested that up-
regulation of β3-AR aggravated the fibrosis of 
cardiac fibroblast cells. In other words, inhibition 
of β3-AR expression in cardiac tissues would be 
beneficial for treating cardiac fibrosis and its 




The findings of this work demonstrate that up-
regulation of β3-AR up-regulates the expressions 
of TGF-β, Smad-2, Col-I and Col-III in rat cardiac 
fibroblasts cells, thus suggesting that up-
regulation of β3-AR aggravates cardiac fibrosis. 
Thus, this present study also indicating that 
down-regulating β3-AR might be a useful 
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